Industry
Biotechnology
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Avi Kapoor
May 31, 2024 | 11:44 am
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 2:45 pm
Portfolio Pulse from Benzinga Newsdesk
April 05, 2024 | 12:10 pm
Portfolio Pulse from Benzinga Newsdesk
April 04, 2024 | 10:03 pm
Portfolio Pulse from Benzinga Newsdesk
April 04, 2024 | 8:13 pm
Portfolio Pulse from Benzinga Insights
April 04, 2024 | 9:18 am
Portfolio Pulse from Benzinga Newsdesk
February 29, 2024 | 9:22 pm
Portfolio Pulse from Benzinga Newsdesk
December 08, 2023 | 2:39 pm
Portfolio Pulse from Charles Gross
December 07, 2023 | 10:17 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.